Consensus Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 16:30:08 13/01/2026 GMT			5-day change	1st Jan Change
25.75 ^EUR	+1.38%		+0.39%	-0.59%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Evolution of the Average Target: Formycon AG

Evolution of the Target Price: Formycon AG

Changes in Analyst Recommendations: Formycon AG

18399efbb62db9e0f.8H6oQg_hixbN6pGJz4cn1jfxOu39cTLXgmtnpzkJwaA.ojPGNk6C_nmhp6TRnO1lnUW5U6m6EmTiyS0y9GZjt-PFBPIJXpPFO5iJ9g~23c3b9dd6968c2a6339d1a2f8d24bb1a

Analysts' recommendations: Formycon AG

11-24	FORMYCON : Berenberg remains its Buy rating	ZD
11-17	FORMYCON : RBC reaffirms its Buy rating	ZD
11-13	FORMYCON : RBC maintains a Buy rating	ZD
02/10/25	FORMYCON : RBC maintains a Buy rating	ZD
02/10/25	Frankfurt Stock Exchange opening: DAX continues to approach its record high	DP
17/09/25	FORMYCON : Gets a Buy rating from RBC	ZD
20/08/25	FORMYCON : Berenberg reiterates its Buy rating	ZD
13/08/25	FORMYCON : Receives a Buy rating from RBC	ZD
13/08/25	FORMYCON : Gets a Buy rating from Warburg Research	ZD
10/07/25	Formycon tops SDax with news on FYB206	DP
10/07/25	FORMYCON : Buy rating from RBC	ZD
27/06/25	FORMYCON : Receives a Buy rating from Hauck & Aufhauser	ZD
27/06/25	Hauck Aufhäuser IB Maintains 'Buy' Rating on Formycon with EUR46 Target	DP
26/06/25	FORMYCON : Receives a Buy rating from Warburg Research	ZD
25/06/25	FORMYCON : RBC remains its Buy rating	ZD
17/06/25	FORMYCON : Buy rating from Warburg Research	ZD
13/05/25	FORMYCON : Hauck & Aufhauser keeps its Buy rating	ZD
13/05/25	FORMYCON : Berenberg reiterates its Buy rating	ZD
12/05/25	FORMYCON : Gets a Buy rating from RBC	ZD
12/05/25	FORMYCON : Warburg Research reaffirms its Buy rating	ZD
31/03/25	FORMYCON : Hauck & Aufhauser remains its Buy rating	ZD
31/03/25	FORMYCON : Buy rating from Warburg Research	ZD
31/03/25	FORMYCON : Berenberg remains its Buy rating	ZD
27/03/25	FORMYCON : Warburg Research reaffirms its Buy rating	ZD
04/03/25	FORMYCON : Hauck & Aufhauser reiterates its Buy rating	ZD

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	FORMYCON AG					+64.79%
	LONZA GROUP AG					+19.85%
	IQVIA HOLDINGS INC.					+6.91%
	BEONE MEDICINES AG					+20.42%
	CELLTRION, INC.					+10.16%
	REVOLUTION MEDICINES, INC.					-24.09%
	MEDPACE HOLDINGS, INC.					-9.49%
	EUROFINS SCIENTIFIC SE					-6.11%
	ICON PUBLIC LIMITED COMPANY					+14.18%
	Average					+10.74%
	Weighted average by Cap.					+7.82%